IRCCS National Neurological Institute C. Mondino Foundation   Report issue

Foundation Phase 2 Phase 4
Founded: Pavia Italy (1917)

Organization Overview

First Clinical Trial
2012
NCT02429596
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

IRCCS Mondino Foundation, Pavia, 27100 Italy | IRCCS National Neurological Institute "C. Mondino" Foundation | IRCCS National Neurological Institute C. Mondino Foundation | Mariangela Rondanelli, IRCCS Mondino Foundation, Pavia

Active Ingredients

Drugs in Phase 4 Trials (1)

risedronate (actonel) (1 trial)

Drugs in Phase 2 Trials (2)

colchicine (colbenemid) (1 trial)

onabotulinumtoxinA (Botox) (1 trial)

Drugs in Other Trials (2)

acmella oleracea (1 trial)

Zingiber officinale (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Epilepsy (Phase 4)

Migraine Disorders (Phase 2)

Motor Neuron Disease (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5